JP3348156B2 - 組換えアビポックスウィルス - Google Patents
組換えアビポックスウィルスInfo
- Publication number
- JP3348156B2 JP3348156B2 JP50771588A JP50771588A JP3348156B2 JP 3348156 B2 JP3348156 B2 JP 3348156B2 JP 50771588 A JP50771588 A JP 50771588A JP 50771588 A JP50771588 A JP 50771588A JP 3348156 B2 JP3348156 B2 JP 3348156B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- promoter
- gene
- recombinant
- site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700663 Avipoxvirus Species 0.000 title claims description 44
- 241000700605 Viruses Species 0.000 claims description 128
- 206010037742 Rabies Diseases 0.000 claims description 65
- 239000000427 antigen Substances 0.000 claims description 53
- 108091007433 antigens Proteins 0.000 claims description 53
- 102000036639 antigens Human genes 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 51
- 238000011081 inoculation Methods 0.000 claims description 48
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 45
- 208000007089 vaccinia Diseases 0.000 claims description 45
- 241000714165 Feline leukemia virus Species 0.000 claims description 29
- 241000700662 Fowlpox virus Species 0.000 claims description 29
- 230000028993 immune response Effects 0.000 claims description 27
- 244000052769 pathogen Species 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 17
- 230000001717 pathogenic effect Effects 0.000 claims description 12
- 241000700584 Simplexvirus Species 0.000 claims description 8
- 241000178270 Canarypox virus Species 0.000 claims description 6
- 241001135961 Amsacta moorei entomopoxvirus Species 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 3
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims description 2
- 101500007117 Bovine leukemia virus Surface protein Proteins 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 210000004681 ovum Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 133
- 239000013612 plasmid Substances 0.000 description 132
- 239000012634 fragment Substances 0.000 description 102
- 210000004027 cell Anatomy 0.000 description 66
- 241000287828 Gallus gallus Species 0.000 description 65
- 235000013330 chicken meat Nutrition 0.000 description 65
- 102000053602 DNA Human genes 0.000 description 47
- 108020004414 DNA Proteins 0.000 description 46
- 239000013598 vector Substances 0.000 description 44
- 241000271566 Aves Species 0.000 description 36
- 238000003780 insertion Methods 0.000 description 36
- 230000037431 insertion Effects 0.000 description 36
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 33
- 208000000666 Fowlpox Diseases 0.000 description 31
- 108091034117 Oligonucleotide Proteins 0.000 description 31
- 241000700618 Vaccinia virus Species 0.000 description 31
- 229960005486 vaccine Drugs 0.000 description 31
- 241000283973 Oryctolagus cuniculus Species 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 30
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 26
- 208000015181 infectious disease Diseases 0.000 description 26
- 230000006798 recombination Effects 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 101710154606 Hemagglutinin Proteins 0.000 description 24
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 24
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 24
- 101710176177 Protein A56 Proteins 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 108091026890 Coding region Proteins 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 22
- 238000005215 recombination Methods 0.000 description 21
- 239000000185 hemagglutinin Substances 0.000 description 20
- 101150082239 G gene Proteins 0.000 description 19
- 238000011144 upstream manufacturing Methods 0.000 description 19
- 230000004044 response Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 17
- 239000011159 matrix material Substances 0.000 description 17
- 108090000288 Glycoproteins Proteins 0.000 description 16
- 241000711450 Infectious bronchitis virus Species 0.000 description 16
- 108700004025 env Genes Proteins 0.000 description 16
- 101150030339 env gene Proteins 0.000 description 16
- 102000003886 Glycoproteins Human genes 0.000 description 15
- 241000714266 Bovine leukemia virus Species 0.000 description 14
- 102000004594 DNA Polymerase I Human genes 0.000 description 14
- 108010017826 DNA Polymerase I Proteins 0.000 description 14
- 230000029087 digestion Effects 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 241000894007 species Species 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 108010005774 beta-Galactosidase Proteins 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000002255 vaccination Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 11
- 102000005936 beta-Galactosidase Human genes 0.000 description 11
- 239000006166 lysate Substances 0.000 description 11
- 101150069452 z gene Proteins 0.000 description 11
- 241000711404 Avian avulavirus 1 Species 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 10
- 238000001114 immunoprecipitation Methods 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 206010022000 influenza Diseases 0.000 description 9
- 229920002477 rna polymer Polymers 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000002356 single layer Substances 0.000 description 8
- 241000712461 unidentified influenza virus Species 0.000 description 8
- 101100484387 Fowlpox virus FPV127 gene Proteins 0.000 description 7
- 108010061100 Nucleoproteins Proteins 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 241000282326 Felis catus Species 0.000 description 6
- 102000011931 Nucleoproteins Human genes 0.000 description 6
- 241000286209 Phasianidae Species 0.000 description 6
- 241000711798 Rabies lyssavirus Species 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 230000014621 translational initiation Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 5
- 241000287219 Serinus canaria Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 230000000405 serological effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000002464 Galactosidases Human genes 0.000 description 4
- 108010093031 Galactosidases Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 101150039660 HA gene Proteins 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 101150110188 30 gene Proteins 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100333573 Bovine leukemia virus env gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000255777 Lepidoptera Species 0.000 description 2
- 101150118742 NP gene Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 102220201851 rs143406017 Human genes 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 241000670670 Amsacta Species 0.000 description 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000700572 Entomopoxvirinae Species 0.000 description 1
- 241000567413 Estigmene Species 0.000 description 1
- 241000567412 Estigmene acrea Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- HHSJMSCOLJVTCX-ZDLURKLDSA-N L-Glutaminyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O HHSJMSCOLJVTCX-ZDLURKLDSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 241000721696 Lymantria Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 101150036031 gD gene Proteins 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 108010077284 hepatitis B surface antigen presurface protein 2 Proteins 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 240000001854 junco Species 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9071187A | 1987-08-28 | 1987-08-28 | |
| US090,711 | 1987-08-28 | ||
| US11033587A | 1987-10-20 | 1987-10-20 | |
| US110,335 | 1987-10-20 | ||
| US18605488A | 1988-04-25 | 1988-04-25 | |
| US186,054 | 1988-04-25 | ||
| US23439088A | 1988-08-23 | 1988-08-23 | |
| US234,390 | 1988-08-23 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001311076A Division JP2002186494A (ja) | 1987-08-28 | 2001-10-09 | 組換えワクシニアウイルス |
| JP2002071416A Division JP3826055B2 (ja) | 1987-08-28 | 2002-03-15 | 組換えアビポックスウイルスによる免疫方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02500879A JPH02500879A (ja) | 1990-03-29 |
| JP3348156B2 true JP3348156B2 (ja) | 2002-11-20 |
Family
ID=27492413
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50771588A Expired - Lifetime JP3348156B2 (ja) | 1987-08-28 | 1988-08-24 | 組換えアビポックスウィルス |
| JP2001311076A Pending JP2002186494A (ja) | 1987-08-28 | 2001-10-09 | 組換えワクシニアウイルス |
| JP2002071416A Expired - Lifetime JP3826055B2 (ja) | 1987-08-28 | 2002-03-15 | 組換えアビポックスウイルスによる免疫方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001311076A Pending JP2002186494A (ja) | 1987-08-28 | 2001-10-09 | 組換えワクシニアウイルス |
| JP2002071416A Expired - Lifetime JP3826055B2 (ja) | 1987-08-28 | 2002-03-15 | 組換えアビポックスウイルスによる免疫方法 |
Country Status (17)
| Country | Link |
|---|---|
| JP (3) | JP3348156B2 (de) |
| KR (1) | KR970011149B1 (de) |
| AR (1) | AR241939A1 (de) |
| AT (1) | AT408549B (de) |
| AU (2) | AU2427588A (de) |
| BE (1) | BE1002134A5 (de) |
| CH (2) | CH679933A5 (de) |
| DE (4) | DE10399032I1 (de) |
| DK (1) | DK175904B1 (de) |
| FR (1) | FR2621487B1 (de) |
| GB (1) | GB2217718B (de) |
| IL (1) | IL87581A0 (de) |
| IT (1) | IT1229484B (de) |
| LU (2) | LU90951I2 (de) |
| NL (4) | NL195051C (de) |
| NZ (1) | NZ225970A (de) |
| WO (1) | WO1989003429A1 (de) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| DE10399032I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| US5286639A (en) * | 1987-09-16 | 1994-02-15 | Nippon Zeon Co., Ltd. | Recombinant avipoxvirus |
| DE3813093A1 (de) * | 1988-04-19 | 1989-11-09 | Immuno Ag | Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung |
| US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
| EP0353851B1 (de) * | 1988-06-24 | 1994-01-19 | Btg International Limited | Nichtessentielle Geflügelpockenvirus-Regionen |
| US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| CA2001001A1 (en) * | 1988-10-21 | 1990-04-21 | Matthew M. Binns | Fowlpox virus promoter |
| US6248333B1 (en) | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
| US5204243A (en) * | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
| US5514375A (en) * | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| FR2668064B1 (fr) * | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| IE68404B1 (en) * | 1990-11-20 | 1996-06-12 | Virogenetics Corp | Measles virus recombinant poxvirus vaccine |
| US5759841A (en) * | 1990-11-20 | 1998-06-02 | Virogenetics Corporation | Immunological composition of measles virus utilizing recombinant poxvirus |
| US5503834A (en) * | 1990-11-20 | 1996-04-02 | Virogenetics Corporation | Measles virus recombinant poxvirus vaccine |
| US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
| US5338679A (en) * | 1991-01-08 | 1994-08-16 | Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada | Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter |
| KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
| US5756101A (en) * | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
| US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
| US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| EP0575544A4 (en) * | 1991-03-20 | 1997-05-21 | Virogenetics Corp | Malaria recombinant poxvirus vaccine |
| DE69233080T2 (de) * | 1991-06-14 | 2004-04-15 | Connaught Technology Corp., Greenville | Rekombinanter hiv-spezifischer impfstoff aus poxviru |
| AU670538B2 (en) * | 1991-07-26 | 1996-07-25 | Virogenetics Corporation | Infectious bursal disease virus recombinant poxvirus vaccine |
| DE69133333T2 (de) * | 1991-08-26 | 2004-07-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
| US5443831A (en) * | 1991-10-29 | 1995-08-22 | University Of Delaware | Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus |
| US6328975B1 (en) | 1992-01-13 | 2001-12-11 | Syntro Corporation | Recombinant swinepox virus |
| US6251403B1 (en) | 1992-01-13 | 2001-06-26 | Syntro Corporation | Recombinant swinepox virus |
| US5869312A (en) * | 1992-01-13 | 1999-02-09 | Syntro Corporation | Recombinant swinepox virus |
| US6497882B1 (en) | 1992-01-13 | 2002-12-24 | Syntro Corporation | Recombinant swinepox virus |
| WO1993014219A1 (en) * | 1992-01-13 | 1993-07-22 | Virogenetics Corporation | Marek's disease virus recombinant poxvirus vaccine |
| US6033904A (en) * | 1992-01-13 | 2000-03-07 | Syntro Corporation | Recombinant swinepox virus |
| US6127163A (en) * | 1992-01-13 | 2000-10-03 | Syntro Corporation | Recombinant swinepox virus |
| EP0662139A1 (de) * | 1992-09-21 | 1995-07-12 | Chiron Corporation | Rekombinierender retrovirus-vektor gegen felv und/oder fiv |
| US6136318A (en) * | 1993-02-26 | 2000-10-24 | Cochran; Mark D. | Recombinant fowlpox viruses and uses thereof |
| US5925358A (en) * | 1993-02-26 | 1999-07-20 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
| AU727278B2 (en) * | 1993-02-26 | 2000-12-07 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof II |
| EP0696204A4 (de) * | 1993-02-26 | 1999-03-31 | Syntro Corp | Rekombinierter geflügelpockenvirus und seine verwendung |
| US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
| US5843742A (en) * | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
| EP0753581A1 (de) | 1995-07-10 | 1997-01-15 | Immuno Ag | Verbesserte rekombinante eukaryotische zytoplasmatische Viren, Methode ihrer Herstellung und ihrer Verwendung als Impfstoffe |
| US5858373A (en) * | 1995-12-01 | 1999-01-12 | Virogenetics Corporation | Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them |
| EP0954593A1 (de) | 1996-07-25 | 1999-11-10 | Therion Biologics Corporation | Rekombinantes pockenvirus für die immunsierung gegen tumorassoziierte antigene. |
| US6106825A (en) * | 1997-05-07 | 2000-08-22 | University Of Florida | Entomopoxvirus-vertebrate gene delivery vector and method |
| AU3910097A (en) * | 1997-08-05 | 1999-03-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Live recombinant vaccine comprising inefficiently or non-replicating vir us |
| US6248582B1 (en) * | 1997-10-08 | 2001-06-19 | Imran Khan | Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV |
| JPH11165762A (ja) | 1997-12-01 | 1999-06-22 | Lintec Corp | チップ体搬送用カバーテープおよび封止構造体 |
| US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| WO2000039302A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| US6545127B1 (en) | 1999-06-28 | 2003-04-08 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
| CZ303468B6 (cs) | 2000-02-23 | 2012-10-03 | Smithkline Beecham Biologicals S. A. | Imunogenní smes a farmaceutická smes |
| ATE396265T1 (de) | 2000-06-28 | 2008-06-15 | Corixa Corp | Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs |
| EP2198882A3 (de) | 2001-01-12 | 2010-10-13 | Novartis Vaccines and Diagnostics, Inc. | Nukleinsäure mukosale Immunisierung |
| MXPA03007862A (es) * | 2001-03-08 | 2004-05-24 | Akzo Nobel Nv | Vacunas de vector basadas en leporipox. |
| JP4499311B2 (ja) * | 2001-04-27 | 2010-07-07 | シャープ株式会社 | 放送受信端末 |
| WO2002089747A2 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| JP5033303B2 (ja) | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用 |
| EP1409694A4 (de) | 2001-07-05 | 2006-02-08 | Chiron Corp | Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen |
| DK1581119T3 (da) | 2001-12-17 | 2013-05-13 | Corixa Corp | Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme |
| RU2544850C2 (ru) | 2003-01-06 | 2015-03-20 | Корикса Корпорейшн | Некоторые аминоалкилглюкозаминидфосфатные производные и их применение |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| WO2005007808A2 (en) | 2003-05-15 | 2005-01-27 | Chiron Corporation | Hiv polynucleotides and polypeptides derived from botswana mj4 |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| CA2580103C (en) | 2004-09-22 | 2021-11-16 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| EP2360175B1 (de) | 2005-11-22 | 2014-07-16 | Novartis Vaccines and Diagnostics, Inc. | Norovirus und sapovirus virusähnliche partikel (vlps) |
| AU2007239095B2 (en) | 2006-01-09 | 2012-05-03 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
| EP2397853B1 (de) | 2006-03-14 | 2014-01-15 | Oregon Health and Science University | Methoden zur Detektion einer Mycobakterium tuberculosis Infektion |
| AU2008221383B2 (en) | 2007-02-28 | 2012-09-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| US20120040367A1 (en) | 2007-10-15 | 2012-02-16 | The University Of Queensland | Construct system and uses therefor |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| WO2010078556A1 (en) | 2009-01-05 | 2010-07-08 | Epitogenesis Inc. | Adjuvant compositions and methods of use |
| US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
| CN102713629B (zh) | 2009-11-20 | 2016-02-24 | 俄勒冈健康科学大学 | 用于检测结核分枝杆菌感染的方法 |
| US20130052221A1 (en) | 2010-02-26 | 2013-02-28 | The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services | Dna-protein vaccination protocols |
| US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
| US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
| WO2012151272A2 (en) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| WO2012177595A1 (en) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| BR112013032410A2 (pt) | 2011-06-24 | 2017-01-17 | Epitogenesis Inc | composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno |
| US20150004144A1 (en) | 2011-12-02 | 2015-01-01 | The General Hospital Corporation | Differentiation into brown adipocytes |
| EP2890720B1 (de) | 2012-08-30 | 2019-07-17 | The General Hospital Corporation | Zusammensetzungen und verfahren zur behandlung von krebs |
| ES2752190T3 (es) | 2012-09-14 | 2020-04-03 | Us Health | Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014172560A1 (en) | 2013-04-17 | 2014-10-23 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
| CA2913155A1 (en) | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
| WO2015073707A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| SG11201606101WA (en) | 2014-02-06 | 2016-08-30 | Genzyme Corp | Compositions and methods for treating and preventing macular degeneration |
| WO2016044707A1 (en) | 2014-09-18 | 2016-03-24 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
| EP3270897A4 (de) | 2015-03-20 | 2018-12-05 | The Regents Of The University Of Michigan | Immunogene zusammensetzungen zur verwendung als impfstoff gegen bordetella |
| WO2016168601A1 (en) | 2015-04-17 | 2016-10-20 | Khalid Shah | Agents, systems and methods for treating cancer |
| CN107708718B (zh) | 2015-04-22 | 2022-01-11 | 西达-赛奈医疗中心 | 用于治疗2型糖尿病的肠内递送的苦味寡肽 |
| US20180346520A1 (en) | 2015-05-13 | 2018-12-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And | Methods and compositions for inducing an immune response using conserved element constructs |
| WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
| US10550379B2 (en) | 2015-06-29 | 2020-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
| WO2017096432A1 (en) | 2015-12-09 | 2017-06-15 | Admedus Vaccines Pty Ltd | Immunomodulating composition for treatment |
| US11285191B2 (en) | 2016-07-26 | 2022-03-29 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Immunostimulatory compositions and uses therefor |
| US10917454B1 (en) | 2019-08-01 | 2021-02-09 | Rohde & Schwarz Gmbh & Co. Kg | System and method for ATC voice quality assurance |
| WO2023070072A1 (en) | 2021-10-21 | 2023-04-27 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Retroelement-generated transcription factor decoys |
| WO2023077147A2 (en) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | T-cell vaccines for patients with reduced humoral immunity |
| WO2023081756A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2023183589A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Rt-dna fidelity and retron genome editing |
| WO2023183588A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods of assessing engineered retron activity, and uses thereof |
| WO2023183627A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna |
| WO2024020346A2 (en) | 2022-07-18 | 2024-01-25 | Renagade Therapeutics Management Inc. | Gene editing components, systems, and methods of use |
| WO2024044673A1 (en) | 2022-08-24 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Dual cut retron editors for genomic insertions and deletions |
| WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK489481A (da) * | 1980-11-10 | 1982-05-11 | Searle & Co | Plasmidvektor og frmgangsmaade til fremstilling deraf |
| US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| JPH0795954B2 (ja) * | 1982-11-30 | 1995-10-18 | アメリカ合衆国 | 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法 |
| FR2563434B1 (fr) * | 1984-04-25 | 1986-07-25 | Transgene Sa | Vaccin contre la rage et procede pour sa preparation |
| WO1986000528A1 (en) * | 1984-07-05 | 1986-01-30 | Genex Corporation | Cloned gene and method for making and using the same |
| DD235669A1 (de) * | 1985-03-26 | 1986-05-14 | Akad Wissenschaften Ddr | Verfahren zur herstellung eines blv-kodierten huellproteins |
| WO1986005806A1 (en) * | 1985-03-29 | 1986-10-09 | National Research Development Corporation | Infectious bronchitis virus spike protein |
| EP0213894A3 (de) * | 1985-08-23 | 1987-10-21 | Advanced Genetics Research Institute | Defektive Viruspartikelimpfstoffe und Verfahren zur Anwendung derselben |
| AU607399B2 (en) * | 1985-09-09 | 1991-03-07 | Cetus Corporation | Infectious recombinant virus vaccine for feline leukemia |
| NZ217645A (en) * | 1985-09-25 | 1991-11-26 | Oncogen | Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations |
| AU602875B2 (en) * | 1985-12-18 | 1990-11-01 | British Technology Group Limited | Newcastle disease virus gene clones |
| AU8075787A (en) * | 1986-09-22 | 1988-04-07 | Australian National University, The | Recombinant poxviruses |
| WO1988002022A1 (en) * | 1986-09-22 | 1988-03-24 | Commonwealth Scientific And Industrial Research Or | Recombinant poxviruses |
| EP0261940A3 (de) * | 1986-09-23 | 1989-07-05 | Applied Biotechnology, Inc. | Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren |
| AU605567B2 (en) * | 1987-03-11 | 1991-01-17 | Nippon Zeon Co., Ltd. | Recombinant avipoxvirus |
| DE10399032I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| GB8724885D0 (en) * | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| FR2632863B2 (fr) * | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| EP0353851B1 (de) * | 1988-06-24 | 1994-01-19 | Btg International Limited | Nichtessentielle Geflügelpockenvirus-Regionen |
| JP3044062B2 (ja) * | 1989-03-08 | 2000-05-22 | ヘルス・リサーチ・インク | 組換えポックスウイルス宿主選択系 |
| WO1992005263A1 (en) * | 1990-09-25 | 1992-04-02 | Cantab Pharmaceuticals Research Limited | Viral defective vaccine produced by transcomplementing cell line |
-
1987
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/de active Pending
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/de active Pending
-
1988
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/en active Application Filing
- 1988-08-24 NL NL8820679A patent/NL195051C/nl not_active IP Right Cessation
- 1988-08-24 JP JP50771588A patent/JP3348156B2/ja not_active Expired - Lifetime
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/de active Pending
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-24 DE DE3890874A patent/DE3890874C5/de not_active Expired - Lifetime
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/ko not_active IP Right Cessation
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 AT AT0900788A patent/AT408549B/de not_active IP Right Cessation
- 1988-08-28 IL IL87581A patent/IL87581A0/xx not_active IP Right Cessation
- 1988-08-29 AR AR88311787A patent/AR241939A1/es active
- 1988-08-29 IT IT8821772A patent/IT1229484B/it active
- 1988-08-29 FR FR888811334A patent/FR2621487B1/fr not_active Expired - Lifetime
- 1988-08-29 BE BE8800978A patent/BE1002134A5/fr not_active IP Right Cessation
- 1988-08-29 NZ NZ225970A patent/NZ225970A/xx unknown
-
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/da active Protection Beyond IP Right Term
-
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
-
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/ja active Pending
-
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/ja not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/fr unknown
-
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/nl unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/fr unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/nl unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/nl unknown
Non-Patent Citations (3)
| Title |
|---|
| Ａｖｉａｎ Ｄｉｓｅａｓｅｓ，Ｖｏｌ．３０，Ｎｏ．１，Ｐ．２４−２７ |
| Ｖｉｒｏｌｏｇｙ，Ｖｏｌ．１５６，Ｐ．３５５−３６５（１９８７年３月） |
| Ｖｉｒｏｌｏｇｙ，Ｖｏｌ．１６０，Ｎｏ．１，（１９８７），Ｐ．２０３−２０９ |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3348156B2 (ja) | 組換えアビポックスウィルス | |
| US5505941A (en) | Recombinant avipox virus and method to induce an immune response | |
| US5174993A (en) | Recombinant avipox virus and immunological use thereof | |
| US5187087A (en) | Recominbant herpesvirus of turkeys and live vector vaccines derived thereof | |
| JP2002514885A (ja) | ポックスウイルス−イヌジステンパーウイルス（ｃｄｖ）組み換え体類および組成物類および前記組み換え体類を用いる方法 | |
| IT9020063A1 (it) | Vaccino di poxvirus ricombinante di herpesvirus | |
| JP2007105040A (ja) | 組換体ポックスウイルス−ネコ感染性腹膜炎ウイルス、その組成物およびそれらの製造および使用方法 | |
| JP2007082551A (ja) | 組換えポックスウイルス−カリシウイルス［ウサギ出血疾患ウイルス（ｒｈｄｖ）］組成物および使用 | |
| US4738846A (en) | Vaccine for vesicular stomatitis virus | |
| JP2007254489A (ja) | Ｈｔｌｖ抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物 | |
| JPH0235079A (ja) | 感染性ウシ鼻気管炎ウイルスの挿入突然変異体 | |
| JP3529134B2 (ja) | 組換えネコヘルペスウイルスのベクターワクチン | |
| US5279965A (en) | Recombinant infectious laryngotracheitis virus | |
| WO2007115385A2 (en) | Transfer plasmidic vector and recombinant canarypox virus | |
| AU761321B2 (en) | Recombinant viruses, vaccines containing them and in vitro cell cultures thereof | |
| CA1341403C (en) | Recombinant a vipox virus | |
| AU725985B2 (en) | Recombinant virus | |
| DK175980B1 (da) | Recombinante vacciniavira og anvendelsen af samme | |
| DK176068B1 (da) | Rekombinant kanaripoxvirus og anvendelsen af samme | |
| DK176165B1 (da) | Rekombinant fjerkræpoxvirus samt anvendelsen af samme | |
| IE60309B1 (en) | Recombinant viruses, vaccines containing them and in vitro cell cultures thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080913 Year of fee payment: 6 |
|
| EXPY | Cancellation because of completion of term |